Citations 1
MonumenTAL-5: A Phase 3 Study of Talquetamab Versus Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Who Received ≥4 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and an Anti-CD38 Monoclonal A
Kumar, Shaji , Trudel, Suzanne , Ma, Xuewen, Olyslager, Yunsi, Thakkar, Payal, Pei, Lixia, Heuck, Christoph, Garfall, Alfred L. , Ocio, Enrique M. , Scott, Emma , Huang, Lin , Terpos, Evangelos
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7292-7293
